RASGRF2 and non-small cell lung carcinoma: In addition, OCLN was the fusion partner in a RASGRF1 fusion from cholangiocarcinoma, 5 RASGRF2 fusions from PDAC and NSCLC, and was previously reported in another RASGRF1 fusion from NSCLC by our group21.